Bharat Book Bureau Provides the Trending Market Research Report on “Global CAR T Cell Therapy Market & Clinical Trials Insight 2028” under the Life Sciences Market Research Report Category. The report offers a collection of superior Market research, Market analysis, competitive intelligence, and Market reports.

Global CAR T Cell Therapy Market & Clinical Trials Insight 2028 Report Highlights:

• Research Methodology
• Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
• Global & Regional Market Insight: Current & Market Forecast 2028
• Approved CAR T Cell Therapies Sales Forecast Till 2028
• Emerging In Vivo Induced CAR T Cell Therapies
• CAR T Cell Therapy Manufacturing Cost Analysis
• CAR T Cell Therapy Approval & Reimbursement Scenario By Country
• Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies
• Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
• CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase

Chimeric antigen receptor (CAR) T cell therapy is novel immunotherapeutic approach which is indicated for the management of cancer. CAR T-cell therapy is a type of therapy in which the T-cells are taken from the blood of the patient, which is then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor). This aids in better recognizing of specific cancer cell antigens. The CAR T-cells are then given back to the patient. To date, 6 CAR T-cell therapy products including Kymriah (tisagenlecleucel), yescarta (axicabtagene), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), and Abecma (idecabtagene vicleucel) have been approved by FDA for the management of wide range of cancers. In addition to this, Relmacabtagene autoleucel have been approved in China.

The introduction of CAR T cell therapies have shown high adoption rates in short span of time has propelled the further research and development activities in this domain. Apart from hematological malignancies, the researchers are also expanding the role of CAR T cell therapies in solid tumors which will propel the growth of market. For instance, a recent research study demonstrated that infusing immune cells into patients has shown early promise by shrinking tumors in digestive system. The interim results demonstrated that tumors in nearly 50% of the 37 patients so far reduced in size after the therapy.

The global CAR T cell therapy market is highly consolidated with several key players. The pharmaceutical giants in the market are increasingly partnering or collaborating with technologies companies to integrate advanced technologies for the betterment of CAR-T therapy or to expand geographical presence. For instance, Bayer and Atara Biotherapeutics entered into worldwide license agreement for the development of next generation ATA3271 which is mesothelin-directed CAR-T cell therapy. The agreement also aims to develop ATA2271, for the management of high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.

Among drug type, Yescarta is currently dominating the market. Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma. Recently in 2022, regulatory bodies expanded the approval of drug for the management of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy. The wide range of therapeutic indications as well as global availability of the drug is the major factors which are the major factors aiding in dominance of these factors.

As per our report findings, the Global CAR T cell therapy market opportunity is expected to surpass US$ 15 Billion by 2028. The development of CAR T cell therapy will gather momentum from the increasing number of investors, designers, and analysts in the guide therapy. Rising frequencies of cancer across the globe together with the relentless technological advancement for dependable and effective cancer treatment is expected to support growth of the worldwide CAR-T cell therapy market. Furthermore, heavy investments on clinical research and development in cell therapy are estimated to boost the market for CAR-T cell therapy in the years to come.

Our report provides information on the globally approved CAR T cell therapies along with their price, dosage, and sales analysis. The report analyzes and forecasts the size of the global CAR-T cell therapy market. The report delivers a full-scale exploration of market dynamics and factors that are manipulating the growth of the global CAR-T cell therapy market. The report also gives competitive analysis of major market players will give a competitive advantage to customers in their respective businesses.

Browse our full report with Table of Content:

https://www.bharatbook.com/report/1344794/global-car-t-cell-therapy-market-clinical-trials-insight

About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,00,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: [email protected]
Website: www.bharatbook.com